152 related articles for article (PubMed ID: 22634531)
61. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
[TBL] [Abstract][Full Text] [Related]
62. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
[TBL] [Abstract][Full Text] [Related]
63. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
64. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A; García-Tapiador AM; Martínez-Ortega E; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Morales F; Ramírez-Torosa C; Martín-Salvago MD; Sánchez-Rovira P
Clin Transl Oncol; 2008 Oct; 10(10):646-53. PubMed ID: 18940745
[TBL] [Abstract][Full Text] [Related]
65. Doxorubicin, paclitaxel and gemcitabine: a Phase I study of a new sequential treatment in stage III B - IV breast cancer.
Ibrahim T; Fabbri M; Frassineti GL; Zoli W; Monti M; Ricotti L; Amadori D
J Chemother; 2003 Oct; 15(5):488-94. PubMed ID: 14598942
[TBL] [Abstract][Full Text] [Related]
66. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
67. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Tu Y; Hershman DL; Bhalla K; Fiskus W; Pellegrino CM; Andreopoulou E; Makower D; Kalinsky K; Fehn K; Fineberg S; Negassa A; Montgomery LL; Wiechmann LS; Alpaugh RK; Huang M; Sparano JA
Breast Cancer Res Treat; 2014 Jul; 146(1):145-52. PubMed ID: 24903226
[TBL] [Abstract][Full Text] [Related]
68. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
[TBL] [Abstract][Full Text] [Related]
69. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Colomer R; Llombart-Cussac A; Lluch A; Barnadas A; Ojeda B; Carañana V; Fernández Y; García-Conde J; Alonso S; Montero S; Hornedo J; Guillem V
Ann Oncol; 2004 Feb; 15(2):201-6. PubMed ID: 14760109
[TBL] [Abstract][Full Text] [Related]
70. A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Xu B; Shen Z; Jiang Z; Guan Z; Zhang X
Asia Pac J Clin Oncol; 2010 Dec; 6(4):320-9. PubMed ID: 21114782
[TBL] [Abstract][Full Text] [Related]
71. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
Delfino C; Caccia G; Gonzáles LR; Mickiewicz E; Rodger J; Balbiani L; Morales DF; Comba AZ; Brosio C
Oncology; 2004; 66(1):18-23. PubMed ID: 15031594
[TBL] [Abstract][Full Text] [Related]
72. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer.
Werner TL; Ray A; Lamb JG; VanBrocklin M; Hueftle K; Cohen AL; Beck AC; Buys SS; Dyess DL; Butler TW; Dumlao TL; Neumayer L; Khong HT
Clin Breast Cancer; 2017 Nov; 17(7):503-509. PubMed ID: 28579139
[TBL] [Abstract][Full Text] [Related]
73. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
74. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
75. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
[TBL] [Abstract][Full Text] [Related]
78. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
79. [Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Li X; Li Y; Yang SE; Ma Y; Wen SJ; Guo L; Guli KZ; Zhao B; Liu W; Hu X
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):916-20. PubMed ID: 22340101
[TBL] [Abstract][Full Text] [Related]
80. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
